RxDoctor Payments Data

Ada Marin, MD

Family Medicine · San Diego, CANPI 1750420931

Payments from drug & device makers

$12,096in general payments, 2019–2025

Across 581 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • Johnson & Johnson$731
  • Novo Nordisk$698
  • GSK$646
  • plus $5K from 43 others

What the payments were for

  • Consulting fees$1,20010%
  • Food & beverage$10,84390%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,096 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$86,800
Medicare patients
177
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab62$109,121
TymlosAbaloparatide18$68,975
JardianceEmpagliflozin43$67,936
FarxigaDapagliflozin Propanediol48$66,599
Xigduo XrDapaglifloz Propaned/Metformin38$52,174
OzempicSemaglutide32$49,546
Teriparatide11$38,348
XareltoRivaroxaban29$38,015
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$36,814
EliquisApixaban31$36,657
JanuviaSitagliptin Phosphate22$34,728
Synjardy XrEmpagliflozin/Metformin Hcl23$32,124
MounjaroTirzepatide25$25,014
Rosuvastatin Calcium426$12,422
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$591$109,12162 claims
Boehringer IngelheimJardiance, Synjardy Xr$190$100,06066 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,551$84,25071 claims
Radius Health, Inc.Tymlos$524$68,97518 claims
Novo NordiskOzempic$698$49,54632 claims
PfizerEliquis, Paxlovid$472$38,08758 claims
Johnson & JohnsonXarelto$731$38,01529 claims
GSKTrelegy Ellipta$646$36,81438 claims
MerckJanuvia$209$34,72822 claims
Lilly USA, LLCMounjaro$543$25,01425 claims
AbbVieNamzaric, Synthroid$1,582$11,05962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →